Nyob rau hauv lub neej niaj hnub no, kev rog rog tau dhau los ua kev sib tw kev noj qab haus huv thoob ntiaj teb, thiab qhov tshwm sim ntawmRetatrutidemuab kev cia siab tshiab rau cov neeg mob uas hnyav dhau. Retatrutide yog ibtriple receptor agonisthom phiajGLP-1R, GIPR, thiab GCGR. Qhov no tshwj xeeb multi-target synergistic mechanism qhia tau tshwj xeeb muaj peev xwm rau poob phaus.
Mechanistically, Retatrutide activatesGLP-1 receptors, uas txhawb nqa cov tshuaj insulin secretion, inhibits glucagon tso tawm, thiab ncua lub plab zom mov, yog li txhim kho satiety thiab txo cov zaub mov noj. Nws activation ntawmGIP receptorsntxiv txhim kho insulin rhiab heev, tswj cov lipid metabolism, thiab ua haujlwm sib koom ua ke nrog GLP-1 kom nthuav dav cov teebmeem yuag. Qhov tseem ceeb tshaj, nws cov activation ntawmGlucagon receptors (GCGR)nce kev siv hluav taws xob, txhim kho hepatic gluconeogenesis inhibition, thiab txo cov rog hauv daim siab - ua ke, cov kev no ua rau kom poob ceeb thawj.
Hauv kev sim tshuaj, qhov poob phaus los ntawm Retatrutide tau zoo kawg li. Hauv 48-lub lim tiam Phase 2 kev tshawb fawb soj ntsuam, cov neeg koom tau txais 12 mg koob tshuaj Retatrutide txhua lub lim tiam poob qhov nruab nrab ntawm24.2% ntawm lawv lub cev hnyav-ib qho txiaj ntsig uas ntau tshaj li ntau cov tshuaj poob phaus thiab ua kom muaj txiaj ntsig ntawm kev phais bariatric. Ntxiv mus, qhov poob phaus tseem txhim kho lub sijhawm; los ntawmlis 72, qhov nruab nrab qhov hnyav txo mus txog kwv yees li28%.
Tshaj li nws qhov hnyav-txo cov nyhuv, Retatrutide kuj qhia tau hais tias muaj kev cog lus zoo hauv kev txhim kho cov teeb meem kev rog. Nws tuaj yeem txo cov ntshav siab, txhim kho lipid profile, txo cov qib triglyceride, thiab muaj kev tiv thaiv kab mob plawv-nqacov txiaj ntsig kev noj qab haus huvrau cov neeg nyob nrog rog.
Post lub sij hawm: Lub Xya hli ntuj-16-2025